Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2126 • ACR Convergence 2023
Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity
Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kvien, Espen Haavardsholm, Siri Lillegraven and Anna-Birgitte Aga, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure (PROM) originating from a EULAR initiative. It might support patient-centred care and…
Abstract Number: 2142 • ACR Convergence 2023
Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors
W. Cliff Rutter, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, Will Cavers, Chen Liu, Rashmi Grover, Lucia Feczko and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…
Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Steven Sambevski⁷ and Wim A Wuyts⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
Abstract Number: 2175 • ACR Convergence 2023
Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study
Marc Schmalzing¹, Charlotte Both², Ines Brueckmann², Javier de Toro Santos³, Tom Sheeran⁴, Herbert Kellner⁵ and Ayman Askari⁶, ¹University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ²Sandoz Hexal AG, Rheumatology, Holzkirchen, Germany, ³University Hospital Coruña, Rheumatology, A Coruña, Spain, ⁴University of Wolverhampton, New Cross Hospital, Wolverhampton, United Kingdom, ⁵Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, ⁶Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Rheumatology, Shropshire, United Kingdom
Background/Purpose: COMPACT is a multi-country, non-interventional study that evaluated the drug persistence, effectiveness, safety and patient-reported outcomes in patients with rheumatoid arthritis (RA), axial spondyloarthritis…
Abstract Number: 2479 • ACR Convergence 2023
Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease
Pierre-Antoine Juge¹, Keigo Hayashi², Gregory McDermott², Kathleen Vanni², Emily Kowalski², Grace Qian², Katarina Bade³, Alene Saavedra², Philippe Dieudé⁴, Paul Dellaripa³, Tracy J. Doyle² and Jeffrey Sparks⁵, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Nintedanib and pirfenidone are antifibrotic drugs indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis. Antifibrotics have…
Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 0054 • ACR Convergence 2023
RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes
Success Amaechi¹, Megan Hanlon², Alyssa Gilmore², Dumitru Anton², Mary Canavan³, Sonia Sundanum⁴, Carl Orr⁵, Douglas Veale⁶, Viviana Marzaioli⁷ and Ursula Fearon⁸, ¹Trinity College Dublin, Mullingar, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ³Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶St.Vincent's University Hosp, Dublin, Ireland, ⁷Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: RA and PsA share various pathogenic features, while also displaying significant differences at the clinical, cellular and molecular levels. In this study, we investigate…
Abstract Number: 0155 • ACR Convergence 2023
Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
Abstract Number: 0321 • ACR Convergence 2023
Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis
Koushik Sangaraju¹, Radu Grovu², Michael Kwark², Elizabeth Cohen², Amira Hassan³ and Anastasia Slobodnick², ¹Staten Island University Hospital - Northwell Health, Staten Island, NY, ²Northwell Health, Staten Island, NY, ³Northwell Health, Brooklyn, NY
Background/Purpose: Osteoarthritis and rheumatoid arthritis cause significant joint replacement morbidity. Proton pump inhibitors (PPIs) may contribute to chronic inflammation and joint degeneration due to side…
Abstract Number: 0391 • ACR Convergence 2023
Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, Ellen Margrethe Hauge¹⁷ and GEORGE KITAS¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
Abstract Number: 0408 • ACR Convergence 2023
The Role of Synovial Biopsy in Evaluating Rheumatoid Arthritis Acitivity in Patients: Findings from a Study of 30 Patients Treated with Adalimumab
Rui Wu and YIlin Peng, the first affilated hospital of Nanchang University, Nanchang, China
Background/Purpose: Rheumatoid arthritis(RA）is a chronic autoimmune disease that is characterized by inflammation and destrction of synovial jionts which result in high disabilty. Treat-to-Target is critical…
Abstract Number: 0425 • ACR Convergence 2023
Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Ioasaf Karafotias, Joshua Rothwell, Maryam Adas, Bechman Katie, Mark Russell, Sam Norton and James Galloway, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…
Abstract Number: 0441 • ACR Convergence 2023
Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Dimitrios Pappas¹, Jacqueline O’Brien¹, Lin Guo¹, Ying Shan¹, Joshua Baker², Gregory Kricorian³, Scott Stryker⁴ and David Collier³, ¹CorEvitas, LLC, Waltham, MA, ²University of Pennsylvania, Philadelphia, PA, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA
Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
Abstract Number: 0743 • ACR Convergence 2023
Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Ted R Mikuls⁵ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There has been limited study of the risk of heart failure (HF) subtypes in RA at a population level, given the requirement for left…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].